GLP-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate PAD.
GLP-1 受體促效劑可減少中度周邊動脈疾病（PAD）患者的主要心血管及肢體不良事件。
J Vasc Surg 2025-06-08
Cardiovascular Effectiveness and Safety of Antidiabetic Drugs in Patients with Type 2 Diabetes and Peripheral Artery Disease: Systematic Review.
2 型糖尿病及周邊動脈疾病患者抗糖尿病藥物的心血管療效與安全性：系統性回顧。
Medicina (Kaunas) 2024-09-28
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis.
在無糖尿病的超重或肥胖成人中，使用GLP-1 RAs或雙重GIP/GLP-1受體激動劑tirzepatide治療的重大不良心血管事件及全因死亡風險：系統性回顧與荟萃分析。
Ther Adv Neurol Disord 2024-09-30
這項研究系統性回顧了16項隨機對照試驗，分析了胰高血糖素樣肽-1受體激動劑（GLP-1 RAs）及雙重GIP/GLP-1 RA tirzepatide在沒有糖尿病的超重或肥胖成人中的心血管及神經保護效果。結果顯示，這些藥物顯著降低重大不良心血管事件（MACE）和全因死亡率的風險，MACE發生率降低至0.79，全因死亡率降至0.80。雖然心血管死亡率有下降趨勢，但未達顯著性。研究建議需進一步探討其對中風的神經保護效果。
PubMedDOI
Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients.
Tirzepatide 與重大不良肢體事件：來自周邊動脈疾病（PAD）和糖尿病患者的多中心實際分析見解。
Diabetes Res Clin Pract 2025-03-06
Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trial.
Liraglutide 改善第二型糖尿病合併周邊動脈疾病患者的周邊灌流，以及血管新生與發炎指標：一項隨機臨床試驗的18個月追蹤結果
Diabetes Obes Metab 2025-04-25
Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study.
第二型糖尿病患者使用SGLT2抑制劑、DPP-4抑制劑或GLP-1受體促效劑後新發周邊動脈疾病的比較：一項以人口為基礎的世代研究
J Am Heart Assoc 2025-05-22
Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
GLP-1 受體促效劑對第二型糖尿病患者重大不良肢體事件風險的影響：隨機臨床試驗的系統性回顧與統合分析
Endocrinol Diabetes Nutr (Engl Ed) 2025-05-24
An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists.
Tirzepatide 與 Glucagon-Like Peptide-1 Receptor Agonists 心血管結局的觀察性研究
JACC Adv 2025-05-30
Glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and advanced CKD: kidney and cardiovascular outcomes in a real-world setting.
第二型糖尿病合併晚期慢性腎臟病患者接受 Glucagon-like peptide-1 receptor agonist 治療之腎臟與心血管結局：真實世界的觀察結果
Clin Kidney J 2025-06-13
Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study.
GLP-1 受體促效劑與 SGLT2 抑制劑對第二型糖尿病患者下肢截肢結果的差異性影響：全國性回溯性世代研究
Diabetes Care 2025-06-25